AnaptysBio Price to Free Cash Flow Ratio 2014-2021 | ANAB

Historical price to free cash flow ratio values for AnaptysBio (ANAB) since 2014. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AnaptysBio Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 28.67 143.64
2021-06-30 25.93 $0.20 129.91
2021-03-31 21.55 $-0.84 0.00
2020-12-31 21.50 $-0.54 0.00
2020-09-30 14.75 $-2.49 0.00
2020-06-30 22.34 $-2.69 0.00
2020-03-31 14.13 $-2.55 0.00
2019-12-31 16.25 $-2.60 0.00
2019-09-30 34.99 $-2.48 0.00
2019-06-30 56.42 $-2.28 0.00
2019-03-31 73.05 $-2.08 0.00
2018-12-31 63.79 $-2.01 0.00
2018-09-30 99.77 $-1.81 0.00
2018-06-30 71.04 $-1.37 0.00
2018-03-31 104.08 $-1.00 0.00
2017-12-31 100.72 $-1.00 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.787B $0.075B
AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00